CYABRA director buys stock and warrants

CYABRA, INC. director James Francis Flanagan increased his exposure on July 10, 2026.

Rhea-AI Filing Summary

CYABRA, INC. director James Francis Flanagan increased his exposure on July 10, 2026. He acquired 114,940 shares of common stock at $0.435 per share in a private placement, bringing his direct common stock holdings to 224,940 shares. He also purchased two series of common stock warrants, each covering 114,940 shares, with exercise prices of $0.50 and $0.45 per share. These warrants were bought in the same private placement and will become exercisable only after requisite stockholder approval, with one series expiring 12 months and the other five years after the initial exercise date.

Filing Explained

The director bought 53,650 shares on July 10; two warrant tranches remain conditional on approval, so ownership changed before any warrant-related dilution.

A Form 4 reports an insider transaction, and this filing was signed on July 13, 2026 for a transaction dated July 10, 2026. A Cyabra director's explanation says the reporting person purchased 53,650 common shares from the issuer in a private placement at $0.435 per share.

The filing also reports purchases of Series A and Series B warrants, each covering up to 53,650 common shares; both warrant types become exercisable only after the requisite stockholder approval.

If those warrants are later exercised and the underlying shares are issued, the additional shares would increase the total share count and reduce existing holders' percentage ownership absent offsetting changes; that dilution is not the current state reported for the warrants.

The relevant milestones are the required stockholder approval and the warrant terms: Series B warrants expire 12 months after their initial exercise date, while Series A warrants expire five years after their initial exercise date.

Insider Trade Summary

Net Buyer: 229,880 shares

Net Buy 3 txns

Insider Flanagan James Francis

Role Director

Bought 229,880 shs ($109K)

Type	Security	Shares	Price	Value
Purchase	Common Stock Warrants (right to buy) F2, F3, F4	114,940	$0.45	$52K
Purchase	Common Stock Warrants (right to buy) F5, F6, F7	114,940	$0.50	$57K
Grant/Award	Common Stock F1	114,940	$0.435	$50K

Holdings After Transaction: Common Stock Warrants (right to buy) — 344,820 contracts (Direct); Common Stock — 224,940 shares (Direct)

Footnotes (7)

1. F1. On July 10, 2026, the Reporting Person purchased 53,650 shares of common stock, par value $0.0001 per share (the "Common Stock"), from the Issuer in a private placement transaction (the "Private Placement") at a purchase price of $0.435 per share.
2. F2. The Reporting Person purchased Series B warrants to purchase up to 53,650 shares of Common Stock (the "Series B Warrants") in the Private Placement.
3. F3. The Series B Warrants will become exercisable upon the receipt of the requisite stockholder approval.
4. F4. The Series B Warrants expire twelve (12) months following the initial exercise date.
5. F5. The Reporting Person purchased Series A warrants to purchase up to 53,650 shares of Common Stock (the "Series A Warrants") in the Private Placement.
6. F6. The Series A Warrants will become exercisable upon the receipt of the requisite stockholder approval.
7. F7. The Series A Warrants expire five (5) years following the initial exercise date.

Key Figures

Common shares acquired: 114,940 shares Purchase price per share: $0.435 Common shares held after transaction: 224,940 shares +3 more

6 metrics

Common shares acquired 114,940 shares Common stock acquired on July 10, 2026 at $0.435 per share

Purchase price per share $0.435 Price paid for each common share in the private placement

Common shares held after transaction 224,940 shares Director’s direct common stock holdings following the July 10, 2026 acquisition

Warrants purchased (Series with $0.50 exercise price) 114,940 warrants Common Stock Warrants acquired July 10, 2026 with $0.50 exercise price

Warrants purchased (Series with $0.45 exercise price) 114,940 warrants Common Stock Warrants acquired July 10, 2026 with $0.45 exercise price

Underlying common shares per warrant series 114,940 shares Each warrant series is exercisable for 114,940 shares of common stock

Key Terms

private placement, Series A warrants, Series B warrants, requisite stockholder approval, +1 more

5 terms

private placement financial

"purchased 53,650 shares of common stock ... in a private placement transaction"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

Series A warrants financial

"purchased Series A warrants to purchase up to 53,650 shares of Common Stock"

Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.

Series B warrants financial

"purchased Series B warrants to purchase up to 53,650 shares of Common Stock"

Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.

requisite stockholder approval regulatory

"will become exercisable upon the receipt of the requisite stockholder approval"

initial exercise date financial

"expire twelve (12) months following the initial exercise date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CYAB (CYABRA, INC.) director James Francis Flanagan acquire on July 10, 2026?

James Francis Flanagan acquired 114,940 shares of CYABRA, INC. common stock at $0.435 per share in a private placement, increasing his direct common stock holdings to 224,940 shares as of that transaction date.

How many CYAB (CYABRA, INC.) warrants did James Francis Flanagan purchase and at what prices?

Flanagan purchased two series of common stock warrants, each for 114,940 underlying shares, with exercise prices of $0.50 and $0.45 per share, in a private placement on July 10, 2026.

When do the CYAB (CYABRA, INC.) Series A and Series B warrants held by James Francis Flanagan become exercisable?

Both the Series A and Series B warrants will become exercisable only upon receipt of the requisite stockholder approval, as described in the transaction footnotes for James Francis Flanagan.

What are the expiration terms of the CYAB (CYABRA, INC.) Series A and Series B warrants purchased by James Francis Flanagan?

The Series B warrants expire 12 months after the initial exercise date, while the Series A warrants expire five years after the initial exercise date, according to the footnotes describing these warrant purchases.

What are James Francis Flanagan’s direct common stock holdings in CYAB (CYABRA, INC.) after the reported transactions?

After acquiring 114,940 shares on July 10, 2026, Flanagan directly holds 224,940 shares of CYABRA, INC. common stock, as reported in the post-transaction ownership field of the Form 4 data.

Are James Francis Flanagan’s CYAB (CYABRA, INC.) warrant purchases open-market or private transactions?

The warrants were purchased in a private placement with CYABRA, INC., as indicated in the footnotes, even though the transaction code reflects a purchase-type transaction rather than an option exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 05:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Flanagan James Francis

(Last) (First) (Middle)

C/O CYABRA, INC.

13 GERSHON SHATZ

(Street)

TEL AVIV 6997543

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYABRA, INC. [ CYAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2026		A		114,940(1)	A	$0.435	224,940	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Warrants (right to buy)(2)	$0.45	07/10/2026		P		114,940		(3)	(4)	Common Stock	114,940	$0.45	114,940	D
Common Stock Warrants (right to buy)(5)	$0.5	07/10/2026		P		114,940		(6)	(7)	Common Stock	114,940	$0.5	229,880	D

Explanation of Responses:

1. On July 10, 2026, the Reporting Person purchased 53,650 shares of common stock, par value $0.0001 per share (the "Common Stock"), from the Issuer in a private placement transaction (the "Private Placement") at a purchase price of $0.435 per share.

2. The Reporting Person purchased Series B warrants to purchase up to 53,650 shares of Common Stock (the "Series B Warrants") in the Private Placement.

3. The Series B Warrants will become exercisable upon the receipt of the requisite stockholder approval.

4. The Series B Warrants expire twelve (12) months following the initial exercise date.

5. The Reporting Person purchased Series A warrants to purchase up to 53,650 shares of Common Stock (the "Series A Warrants") in the Private Placement.

6. The Series A Warrants will become exercisable upon the receipt of the requisite stockholder approval.

7. The Series A Warrants expire five (5) years following the initial exercise date.

	/s/ Yael Sandler, Attorney-in-Fact	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)